Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by Guggenheim

Investment analysts at Guggenheim began coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report released on Wednesday, Benzinga reports. The firm set a “buy” rating and a $70.00 price target on the stock. Guggenheim’s price objective would indicate a potential upside of 97.91% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Citigroup began coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Needham & Company LLC initiated coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They set a “buy” rating and a $56.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Stock Down 9.5%

FTH opened at $35.37 on Wednesday. The stock’s fifty day simple moving average is $31.81. The firm has a market cap of $913.96 million, a price-to-earnings ratio of -0.25 and a beta of -0.28. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. Equities analysts forecast that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Anand Kiran Parikh purchased 2,806 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson purchased 9,391 shares of the stock in a transaction on Wednesday, June 24th. The stock was bought at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the acquisition, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This trade represents a 53.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 49,494 shares of company stock worth $1,188,822 over the last three months. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in FTH. Citadel Advisors LLC bought a new position in shares of Sensei Biotherapeutics during the second quarter worth approximately $307,000. Alyeska Investment Group L.P. bought a new stake in Sensei Biotherapeutics in the 2nd quarter valued at $3,610,000. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Finally, Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.